Skip to main content
Primary hyperoxaluria-mapping impact and gaining insights
In September, while attending the Annual 2019 Global Genes Patient Advocacy Summit in San Diego, our RARE Revolution team had the privilege of hosting a roundtable in partnership with Dicerna Pharmaceuticals and the Oxalosis and Hyperoxaluria Foundation (OHF). Rebecca, CEO of RARE Revolution recounts their individual stories and collective experiences. (Page 54-Page 58)